Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia

Romiplostim is a Food and Drug Administration (FDA)-approved therapy for immune thrombocytopenia (ITP). Biosimilar is a biological product that has no clinical meaningful difference from an existing FDA-approved reference product. It has a potential of lowering health-care-related cost. Biosimilar o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrakala, S., Toshniwal, Manoj, Halvawala, Mitesh, Padwal, Namita, Sidharthan, Neeraj, Malhotra, Pankaj, Prashantha, B., Ballikar, Riya, Shah, Sandip, Apte, Shashikant, Viswanathan, T. Kasi, Ramanan, Vijay, Sharma, Akhilesh, Pawar, Dattatray, Pawar, Roshan, Shahavi, Vinayaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247600/
https://www.ncbi.nlm.nih.gov/pubmed/37304488
http://dx.doi.org/10.1007/s12288-022-01602-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247600/
https://www.ncbi.nlm.nih.gov/pubmed/37304488
http://dx.doi.org/10.1007/s12288-022-01602-5

Ejemplares similares